The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.

Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds. 

ResMed beat Wall Street analysts’ projections for sales growth for the second quarter of 2021, announced exit of its portable oxygen market.

EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.